Bausch Health Companies Inc. (BHC)
Automate Your Wheel Strategy on BHC
With Tiblio's Option Bot, you can configure your own wheel strategy including BHC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BHC
- Rev/Share 26.4872
- Book/Share 72.8855
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC -0.0248
- MktCap 1696234867.0
- FreeCF/Share 3.3974
- PFCF 1.3773
- PE -39.0356
- Debt/Assets 0.0
- DivYield 0
- ROE 0.047
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by 2030, driven by an 11.87% CAGR. Increasing emphasis on physical appearance and the popularity of minimally invasive procedures fuel demand, while the Asia-Pacific region sees rapid expansion due to urbanization and rising incomes. Key players like Allergan and Galderma lead the way. For insights and strategic opportunities, explore historical data and forecasts included in this comprehensive market report. The facial injectable market is poised for significant growth, with a rise from US$18.310 billion in 2025 to US$32.083 billion by …
Read More
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient f.
Read More
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
Read More
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Published: April 22, 2025 by: Reuters
Sentiment: Positive
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Read More
Bausch (BHC) Moves 13.3% Higher: Will This Strength Last?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Bausch + Lomb recalls some of its implantable eye lenses
Published: March 27, 2025 by: Reuters
Sentiment: Negative
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
Read More
Bausch Health to Announce First Quarter Results on April 30
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Read More
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Read More
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B …
Read More
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Read More
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
Published: March 14, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P.
Read More
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment.
Read More
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.
Read More
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call.
Read More
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago.
Read More
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24.
Read More
Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth
Read More
About Bausch Health Companies Inc. (BHC)
- IPO Date 1994-03-29
- Website https://www.bauschhealth.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Thomas J. Appio
- Employees 20700